CLINUVEL delivers ninth consecutive revenues growth & profit
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Total revenues increased significantly, driven by robust demand for SCENESSE® treatment among patients, while expenses also rose due to clinical program costs. The company declared an annual dividend, marking the eighth consecutive year of dividend distribution, reflecting its commitment to returning value to shareholders. Clinuvel's cash reserves have also grown, providing a solid foundation for future growth and diversification plans.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clinuvel Pharmaceuticals Limited on 6ix
In the deck
Earlier from Clinuvel Pharmaceuticals
- Appendix 4E and Annual Report to Shareholders 2025
- CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
- CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
- Study confirms NB-UVB needed to activate repigmentation
- CLINUVEL management update
Later from Clinuvel Pharmaceuticals
- Investor Presentation
- SCENESSE efficacy in vitiligo - new cases presented to EADV
- EMA approves year-round SCENESSE treatment
- CLINUVEL to advance novel pharmaceutical formulations in preclinical program
- CLINUVEL advances new formulations in preclinical program
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals